Literature DB >> 22136209

In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.

Haggi Mazeh1, Joy Benavidez, Jennifer L Poehls, Linda Youngwirth, Herbert Chen, Rebecca S Sippel.   

Abstract

BACKGROUND: About 5% of nonmedullary thyroid cancers (NMTCs) are familial. Most patients with a family history of thyroid cancer do not meet the definition of familial NMTC (FNMTC; two or more affected family members). The aim of this study was to determine whether patients with a family history of NMTC, but who do not meet the definition of FNMTC, have more aggressive disease.
METHODS: A database of 1502 thyroidectomies was reviewed and 358 patients with NMTC who did not have a family history of benign thyroid disease and who underwent thyroidectomy from January 1994 to December 2008 were identified. These included 324 (90%) patients with papillary thyroid carcinoma (PTC), 24 (7%) with follicular thyroid cancer, and 10 (3%) with anaplastic or Hürthle cell carcinoma. Among them, those with and without a family history of NMTC in first-degree relatives were compared. Then patients with only one affected family member were compared with FNMTC patients.
RESULTS: Thirty-seven (10%) patients had a family history of thyroid cancer, all to of which had PTC. Patients with a family history of NMTC had a similar tumor size than those without (2±0 vs. 2.1±0 cm, p=0.72) but they were significantly younger (43±3 vs. 49±1 years, p=0.04), and more likely to have multicentricity (48% vs. 22%, p=0.01), malignant lymph nodes (22% vs. 11%, p=0.02), and local invasion to surrounding tissues (5.4% vs. 0.6%, p=0.007). They also had a higher recurrence rate (24% vs. 12%, p=0.03) than patients without a family history. Interestingly, patients with only one affected family member were similar to FNMTC patients with respect to age (44±4 vs. 40±3 years, p=0.4), tumor size (2±0 vs. 1.9±0 cm, p=0.65), rate of multicentricity (44% vs. 52%, p=0.57), malignant lymph nodes (22% vs. 21%, p=0.93), local invasiveness (5.5% vs. 11%, p=0.59), and disease recurrence (28% vs. 21%, p=0.56).
CONCLUSION: Patients with NMTC having a family history of thyroid cancer have more aggressive disease, regardless of whether they meet the current definition of FNMTC regarding number of affected family members. Therefore, any positive family history should be considered a risk factor for more aggressive thyroid carcinoma.

Entities:  

Mesh:

Year:  2011        PMID: 22136209     DOI: 10.1089/thy.2011.0192

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  33 in total

Review 1.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

Review 2.  Controversies in familial thyroid cancer 2014.

Authors:  Orlo H Clark
Journal:  Ulus Cerrahi Derg       Date:  2014-06-01

Review 3.  An update on familial nonmedullary thyroid cancer.

Authors:  Sabrine A Ammar; Wilson M Alobuia; Electron Kebebew
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Clinical Analysis of Familial Nonmedullary Thyroid Carcinoma.

Authors:  Qiang Zhang; Shuai Yang; Xian-ying Meng; Guang Chen; Ren-zhu Pang
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

Review 6.  Genetic predisposition for nonmedullary thyroid cancer.

Authors:  Rebecca Nagy; Matthew D Ringel
Journal:  Horm Cancer       Date:  2014-10-22       Impact factor: 3.869

7.  RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study.

Authors:  Matteo Landriscina; Maria Iole Natalicchio; Olga Lamacchia; Antonella Conserva; Annamaria Piscazzi; Anna Ciampolillo; Matteo Zingrillo; Antonio Pennella; Pantaleo Bufo; Giulia Vita; Raffaele Antonetti; Eugenio Maiorano; Francesco Giorgino; Mauro Cignarelli
Journal:  Oncol Lett       Date:  2015-06-17       Impact factor: 2.967

Review 8.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

Review 9.  The impact of family history on non-medullary thyroid cancer.

Authors:  I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito
Journal:  Eur J Surg Oncol       Date:  2016-08-11       Impact factor: 4.424

10.  BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.

Authors:  Jason D Prescott; Peter M Sadow; Richard A Hodin; Long Phi Le; Randall D Gaz; Gregory W Randolph; Antonia E Stephen; Sareh Parangi; Gilbert H Daniels; Carrie C Lubitz
Journal:  Surgery       Date:  2012-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.